ReCode Therapeutics Receives U.S. FDA Orphan Drug Designation for RCT1100 for the Treatment of Primary Ciliary Dyskinesia

MENLO PARK, Calif.–(BUSINESS WIRE)–ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for RCT1100 for the treatment of primary ciliary dyskinesia (PCD). RCT1100 is a novel investigational therapy being developed to treat PCD caused by pathogenic mutations in the DNAI1 gene. PCD is a rar
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks